Head-to-head evidence
Darunavir vs Tipranavir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV protease · full HIV pipeline
Darunavir · Prezista
Marketed by Johnson & Johnson
NCT00110877 · Phase 3 · completed
The study randomly assigned 604 participants to darunavir/ritonavir or an active lopinavir/ritonavir comparator, but it was open-label rather than blinded. Its primary endpoint was a surrogate virologic measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: September 2027 · NCT06338826 (registry estimate)
Tipranavir · Aptivus
Marketed by Boehringer Ingelheim
NCT00144170 · Phase 3 · completed
The trial randomized participants to an active comparator and included 882 enrolled participants, with 863 in the reported efficacy denominators, but the registry does not clearly report masking. Both primary virologic endpoints favored tipranavir with statistically significant comparisons; however, the primary outcomes were virologic surrogate measures rather than hard clinical outcomes, so the evidence is rated moderate.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Darunavir's landscape · Tipranavir's landscape